Key result
In silico molecular docking demonstrated that Hesperidin and FIOMC are promising broad-spectrum candidates for inhibiting various strains of Enterovirus-A71 3C protease, with Hesperidin exhibiting superior docking scores.
Why the study?
Current research on EV-A71 3C protease strains has been separate and unrelated, necessitating testing of antiviral agents across multiple virus strains or mutations.
In silico molecular docking identifies Hesperidin as a promising broad-spectrum candidate for inhibiting various strains of EV-A71 3C protease.
Early-phase 3Cpro inhibitor data in HFMD warrant clinical caution; leaves open multi-strain efficacy and need for larger trials.
Hand, foot, and mouth disease (HFMD) is a common infection that primarily affects children in preschool and kindergarten; however, there is yet no vaccination or therapy available. Despite the fact that current research is only focused on numerous strains of Enterovirus—A71 (EV-A71) 3C protease (3C pro ), these investigations are entirely separate and unrelated. Antiviral agents must therefore be tested on several EV strains or mutations. In total, 21 previously reported inhibitors were evaluated for inhibitory effects on eight EV-A71 3C pro , including wild-type and mutant proteins in this study, and another 29 powerful candidates with inhibitory effects on EV-A71 were investigated using the molecular docking approach. This method is to determine the broad-spectrum of the antiviral agents on a range of strains or mutants because the virus frequently has mutations. Even though Rupintrivir is reported to pass phase I clinical trial, 4-iminooxazolidin-2-one moiety (FIOMC) was shown to have a broader anti-3C pro spectrum than Rupintrivir. Meanwhile, Hesperidin possessed a better 3C pro inhibitory capability than FIOMC. Thus, it could be considered the most promising candidate for inhibiting various strains of EV-A71 3C pro proteins in the newly anti-EV compounds group. Furthermore, the mutation at E71A has the most significant impact on the docking results of all ligands evaluated. Future in vitro experiments on Hesperidin’s ability to inhibit 3C pro activity should be conducted to compare with FIOMC’s in vitro results and validate the current in silico work.
No takes yet. Share an insight, caveat, or question.
Le et al. (2022) studied Hand, foot, and mouth disease (Enterovirus-A71). Hesperidin and FIOMC vs. Rupintrivir was evaluated on Docking score (Kcal/mol). In silico molecular docking demonstrated that Hesperidin and FIOMC are promising broad-spectrum candidates for inhibiting various strains of Enterovirus-A71 3C protease, with Hesperidin exhibiting superior docking scores.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: